Nathan Martin

3PUBLICATIONS
29CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Jan 21, 2026
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.

Melissa Alsina, Nina Shah, Sundar Jagannath

|Jul 16, 2025
Distinct patient, tumour and chimeric antigen receptor T-cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma.

Nathan Martin, Ethan Thompson, Nicholas Stong

|Jul 24, 2023
Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel.

Bruno Paiva, Irene Manrique, Julie Rytlewski

Pageof 1

Frequent Collaborators

2 joint publications

Bruno Paiva

2 joint publications

Timothy Campbell

2 joint publications

Jesús G Berdeja

2 joint publications

Noopur S Raje